RSCM
PETX

Rail-Splitter Capital Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Rail-Splitter Capital Management’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-25,000
Closed -$189K – 54
2013
Q2 		$189K Buy
+25,000
New +$198K 0.08% 47

Other funds holding PETX

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Rail-Splitter Capital Management's PETX Position: Q3 2013 in Review

Rail-Splitter Capital Management sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2013, closing a stake of 25,000 shares — an estimated $189K sold.

Rail-Splitter Capital Management first reported a position in PETX in Q2 2013 and held it in 1 quarter. The position peaked at $189K in Q2 2013. 32 funds tracked by Wall St. Rank hold PETX as of Q3 2013.

  • Rail-Splitter Capital Management reported no remaining Aratana Therapeutics, Inc. position as of Q3 2013 after selling out during the quarter.
  • Rail-Splitter Capital Management sold 25,000 Aratana Therapeutics, Inc. shares in Q3 2013, an estimated $189K.
  • Rail-Splitter Capital Management first reported a position in Aratana Therapeutics, Inc. in Q2 2013 and held it in 1 quarter.
  • Rail-Splitter Capital Management's Aratana Therapeutics, Inc. position peaked at $189K in Q2 2013.
  • 32 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2013.

Based on Rail-Splitter Capital Management's 13F filing for Q3 2013, filed 9 Oct 2013.